@article{d246d6215b334263a44a8a997cc4cd33,
title = "Ixekizumab survival in heavily pretreated patients with psoriasis: A two-year single-centre retrospective study",
abstract = "The long-term effect of intra-anti-interleukin-17-class switch on drug survival is unclear. The aim of this study was to evaluate the efficacy and long-term survival of ixekizumab in bio-experienced psoriatic patients with and without previous exposure to anti-interleukin-17 treatment. Retrospective search of a tertiary medical centre database for 2017 to 2019 yielded 73 patients treated with ixekizumab: 50 previously exposed to secukinumab and 23 anti-interleukin-17-na{\"i}ve. Median baseline Psoriasis Area Severity Index (PASI) was 23.0. Median number of received biologics was 4. Mean drug survival was 16.4 and 16.8 months in the antiinterleukin-17-exposed and na{\"i}ve groups, respectively (p = 0.878). There was no between-group difference in proportion of patients achieving ≥ 75 PASI response. At study end, 25 anti-interleukin-17-exposed patients (50.0%) and 17 anti-interleukin-17-na{\"i}ve patients (73.9%) were still on ixekizumab. The use of multiple previous biologic treatments was associated with substantially reduced ixekizumab survival. In conclusion, previous anti-interleukin-17-exposure was associated with an initially favourable response and did not further reduce ixekizumab survival.",
keywords = "Anti-IL-17, Drug survival, Ixekizumab, Psoriasis, Secukinumab, Switch",
author = "Shany Sherman and Ory Zloczower and Yehonatan Noyman and Iris Amitay-Laish and Emmilia Hodak and Lev Pavlovsky",
note = "Publisher Copyright: {\textcopyright} 2020, Medical Journals/Acta D-V. All rights reserved.",
year = "2020",
doi = "10.2340/00015555-3714",
language = "אנגלית",
volume = "100",
pages = "1--5",
journal = "Acta Dermato-Venereologica",
issn = "0001-5555",
publisher = "Medical Journals Sweden AB",
number = "19",
}